Ambee Pharmaceuticals PLC (DSE: AMBEEPHA)
Bangladesh
· Delayed Price · Currency is BDT 751.30
-3.60 (-0.48%)
At close: Jan 29, 2025
Ambee Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Revenue | 226.3 | 219.3 | 198.1 | 180.99 | 98.98 | 285.3 | Upgrade
|
| Revenue Growth (YoY) | 8.13% | 10.71% | 9.45% | 82.86% | -65.31% | -11.18% | Upgrade
|
| Cost of Revenue | 106.07 | 103.04 | 92.47 | 83.62 | 58.27 | 134.03 | Upgrade
|
| Gross Profit | 120.23 | 116.26 | 105.63 | 97.37 | 40.71 | 151.27 | Upgrade
|
| Selling, General & Admin | 107.78 | 103.85 | 92.46 | 82.51 | 47.99 | 139.77 | Upgrade
|
| Operating Expenses | 107.78 | 103.85 | 92.46 | 82.51 | 47.99 | 139.77 | Upgrade
|
| Operating Income | 12.44 | 12.41 | 13.17 | 14.86 | -7.28 | 11.5 | Upgrade
|
| Interest Expense | - | -0.58 | -2.49 | -4.62 | -5 | -6.56 | Upgrade
|
| Interest & Investment Income | 0.51 | - | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0 | 0 | -0 | - | 0 | 0 | Upgrade
|
| EBT Excluding Unusual Items | 12.95 | 11.83 | 10.68 | 10.23 | -12.28 | 4.94 | Upgrade
|
| Pretax Income | 12.95 | 11.83 | 10.68 | 10.23 | -12.28 | 4.94 | Upgrade
|
| Income Tax Expense | 3 | 2.15 | 1.59 | 2.18 | 0.73 | 1.3 | Upgrade
|
| Net Income | 9.95 | 9.68 | 9.09 | 8.06 | -13.01 | 3.64 | Upgrade
|
| Net Income to Common | 9.95 | 9.68 | 9.09 | 8.06 | -13.01 | 3.64 | Upgrade
|
| Net Income Growth | -5.48% | 6.53% | 12.79% | - | - | 8.01% | Upgrade
|
| Shares Outstanding (Basic) | 2 | 2 | 2 | 2 | 2 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 2 | 2 | 2 | 2 | 2 | 2 | Upgrade
|
| EPS (Basic) | 4.15 | 4.03 | 3.79 | 3.36 | -5.42 | 1.52 | Upgrade
|
| EPS (Diluted) | 4.15 | 4.03 | 3.79 | 3.36 | -5.42 | 1.52 | Upgrade
|
| EPS Growth | -5.48% | 6.53% | 12.79% | - | - | 8.01% | Upgrade
|
| Free Cash Flow | -110.35 | -68.12 | -35.34 | -74.71 | -5.45 | -12.68 | Upgrade
|
| Free Cash Flow Per Share | -45.98 | -28.39 | -14.72 | -31.13 | -2.27 | -5.28 | Upgrade
|
| Dividend Per Share | 1.000 | 1.000 | 1.500 | 1.000 | - | 1.500 | Upgrade
|
| Dividend Growth | -33.33% | -33.33% | 50.00% | - | - | -50.00% | Upgrade
|
| Gross Margin | 53.13% | 53.01% | 53.32% | 53.80% | 41.13% | 53.02% | Upgrade
|
| Operating Margin | 5.50% | 5.66% | 6.65% | 8.21% | -7.36% | 4.03% | Upgrade
|
| Profit Margin | 4.40% | 4.42% | 4.59% | 4.45% | -13.14% | 1.27% | Upgrade
|
| Free Cash Flow Margin | -48.76% | -31.06% | -17.84% | -41.28% | -5.51% | -4.45% | Upgrade
|
| EBITDA | 17.9 | 18.26 | 20.16 | 19.64 | -1.67 | 18.12 | Upgrade
|
| EBITDA Margin | 7.91% | 8.32% | 10.18% | 10.85% | -1.69% | 6.35% | Upgrade
|
| D&A For EBITDA | 5.46 | 5.84 | 6.99 | 4.79 | 5.61 | 6.62 | Upgrade
|
| EBIT | 12.44 | 12.41 | 13.17 | 14.86 | -7.28 | 11.5 | Upgrade
|
| EBIT Margin | 5.50% | 5.66% | 6.65% | 8.21% | -7.36% | 4.03% | Upgrade
|
| Effective Tax Rate | 23.15% | 18.16% | 14.90% | 21.25% | - | 26.39% | Upgrade
|
| Advertising Expenses | - | 1.12 | 1.43 | 4.58 | 0.93 | 3.07 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.